European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis.

– Approval based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was durable at one year with every 12-week dosing 1-4 – SKYRIZI™ (risankizumab), a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit, offers moderate to severe psoriasis patients a new therapeutic option 5 – Psoriasis is a chronic condition affecting 125 million people worldwide (more than 225.000 people in Belgium 12) and many patients still do not reach treatment goals or lose treatment response over time 6...